The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Baseline characteristics of patients enrolled in the BERING CRC study
Sebastian Stintzing, MD, Charite University Hospital, Berlin, Germany, comments on the trial design and preliminary data of the Phase IV BERING CRC trial (NCT04673955), a European real-world study aiming to assess the efficacy and safety of encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer. Initial data from 40 patients have revealed the treatment combination to be safe, with efficacy similar to that seen in the Phase III BEACON CRC (NCT02928224) trial. No serious adverse events have additionally been reported so far. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
